Silence Therapeutics (SLN) Income towards Parent Company (2024 - 2026)

Silence Therapeutics has reported Income towards Parent Company for 3 years, with the latest figure at -$15.0 million in Q1 2026.

• Quarterly Income towards Parent Company rose 47.57% year-over-year to -$15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$75.0 million (down 25.98% YoY) and the FY2025 annual result came in at -$88.6 million, down 165.72% from the prior year.
• Income towards Parent Company fell to -$15.0 million in Q1 2026 per SLN's latest filing, from -$11.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $24.3 million in Q4 2024 and troughed at -$35.5 million in Q3 2024.
• A 3-year average of -$15.2 million and a median of -$19.8 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company tumbled 1134.0% in 2025, then jumped 47.57% in 2026.
• Over 3 years, Income towards Parent Company stood at $24.3 million in 2024, then slumped by 148.51% to -$11.8 million in 2025, then dropped by 27.08% to -$15.0 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$15.0 million, -$11.8 million, and -$21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.